Cetilistat

DB06586InvestigationalSmall molecule

Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

Mechanism: Cetilistat is a gastrointestinal lipase inhibitor that blocks fat digestion and absorption, leading to reduced energy intake, and thus weight loss. It is distinct from most other anti-obesity agents as it does not act on the brain to reduce appetite, but acts peripherally. The compound remains in the gastrointestinal tract with no significant absorption into the body.
Curator reviewed
Primary indication: Investigated for use/treatment in obesity.Curator reviewed
Formula / weight: C₂₅H₃₉NO₃ · 401.5821 g/mol (avg)
Code names: ATL-962

Resolves to

Compound

UNIILC5G1JUA39CAS282526-98-1ChEMBLCHEMBL2103825ChEBI134721PubChem9952916

Structure

InChIKeyMVCQKIKWYUURMU-UHFFFAOYSA-NSMILESCCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1

Targets

P07098LIPFP16233PNLIPQ9Y5X9LIPG

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cetilistat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account